Investing.com -- Catalent (NYSE:CTLT), a contract development and manufacturing organization (CDMO), reported results for Q1 of fiscal 2025 that missed analyst expectations.
The company posted a loss per share of $0.13, significantly worse than the earnings per share (EPS) of $0.03 that analysts expected.
Revenue came in at $1.02 billion, also below the consensus estimate of $1.06 billion.
“Our first quarter fiscal 2025 results reflect the continued momentum in our business and underscore our customers’ continued confidence in Catalent. Financial highlights in the quarter included double-digit year-over-year growth in both non-COVID revenue and adjusted EBITDA, while also delivering positive free cash flow,” said Alessandro Maselli, President and CEO of Catalent.
In its Biologics segment, Catalent saw net revenue rise 3.1% year-over-year to $461 million, though this figure lagged behind the expected $476.2 million.
Meanwhile, Pharmaceuticals&Consumer Health achieved $563 million in net revenue, marking a 5.2% year-over-year increase, and also slightly under the forecast of $563.9 million.
Catalent’s adjusted EBITDA reached $125 million, representing an 8.7% year-over-year gain, but significantly short of the $164.8 million analysts anticipated.
Related Articles
Catalent reports Q1 loss, misses market expectations
R1 RCM reports mixed Q3 results, revenue beats estimates
Factbox-Airlines suspend flights as Middle East tensions rise
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.